Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Locally advanced unresectable pancreatic ductal adenocarcinoma
Data

Cancers·Locally advanced unresectable pancreatic ductal adenocarcinoma

DataLocally advanced unresectable pancreatic ductal adenocarcinoma

Back to the Locally advanced unresectable pancreatic ductal adenocarcinoma hub →68 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

68

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Eileen M. O'Reilly, Gemcitabine + nab-paclitaxel, FOLFIRINOX / mFOLFIRINOX and the tags subtype-page, gastrointestinal.
Cancer
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Shares Resectable, borderline resectable and unresectable, CA 19-9, Whipple procedure (pancreaticoduodenectomy), Obstructive jaundice and biliary obstruction and the tags subtype-page, gastrointestinal.
Cancer
Pancreatic acinar cell carcinoma
Shares Whipple procedure (pancreaticoduodenectomy), Eileen M. O'Reilly, FOLFIRINOX / mFOLFIRINOX, Pancreatic cancer (KEGG map) and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Resection margins (R0 / R1 / R2), Whipple procedure (pancreaticoduodenectomy), Cancer cachexia, Pancreatic cancer (KEGG map) and the tags subtype-page, gastrointestinal.
Cancer
Localised anal squamous cell carcinoma (stage I to III)
Shares Chemoradiation (chemoradiotherapy, CRT), PET/CT, Fluorouracil (5-FU), Capecitabine and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Whipple procedure (pancreaticoduodenectomy), KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Metastatic and recurrent anal squamous cell carcinoma
Shares Fluorouracil (5-FU), SBRT / SABR (stereotactic radiotherapy), Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.

technologies

13

Biliary stenting and drainage Cytotoxic chemotherapy FAPI PET Hypofractionated radiotherapy Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)Irreversible electroporation (NanoKnife)KRAS & RAS inhibitors MR-guided adaptive radiotherapy PET/CT Platinum agents SBRT / SABR (stereotactic radiotherapy)Topoisomerase-I inhibitors (and ADC payloads)Tumour treating fields (TTFields)

targets

2

drugs

9

ApprovedOral fluoropyrimidine prodrug (antimetabolite)

Capecitabine · Xeloda

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

ApprovedFluoropyrimidine antimetabolite

Fluorouracil (5-FU) · Adrucil / Efudex

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedNucleoside analogue (deoxycytidine)

Gemcitabine · Gemzar / Infugem

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

ApprovedDevice (tumour treating fields)

Optune / Optune Pax (TTFields) · Optune

Phase 2Small-molecule RAS(ON) G12D-selective inhibitor

companies

7

Eli Lilly (incl. Loxo)GERCOR Ipsen Mast Therapeutics Novocure Revolution Medicines Roche / Genentech

pathways

3

Cancer cachexia Fibroblast activation, desmoplasia & matrix stiffness Pancreatic cancer (KEGG map)

terms

11

CA 19-9 Cancer cachexia Chemoradiation (chemoradiotherapy, CRT)Desmoplasia (tumour stroma)Locally advanced and locoregional disease Obstructive jaundice and biliary obstruction Resectable, borderline resectable and unresectable Resection margins (R0 / R1 / R2)Stenting (biliary, oesophageal, airway)Stereotactic body radiotherapy (SBRT / SABR)Whipple procedure (pancreaticoduodenectomy)

trials

11

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC LAP07 PANOVA-3 RASolute 302 Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

ideas

2

Coverage-with-evidence registries for MR-guided and adaptive radiotherapy Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3

people

6

Albert C. Koong Eileen M. O'Reilly Hedy L. Kindler Theodore S. Hong Theodore S. Lawrence Tobias Janowitz

key papers

4

Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)LAP07: chemoradiotherapy versus chemotherapy after four months of gemcitabine in locally advanced pancreatic cancer LAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Add 11 pancreatic cancer subtype pages · diff · file

Wikipedia

Pancreatic cancer

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Locally advanced unresectable pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/locally-advanced-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id locally-advanced-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.